Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX-PID in Healthy Male Volunteers with Circulating Neutralizing Antibodies Against AAV

The primary objective of this study is to evaluate the **safety**, **tolerability**, **pharmacokinetics**, and **pharmacodynamics** of VTX-PID in healthy male volunteers. This assessment is crucial for determining the initial human response to VTX-PID, which is essential for understanding its potential therapeutic applications and ensuring patient safety in future clinical trials. The study focuses on individuals with circulating neutralizing antibodies against AAV, providing insights into the interaction between VTX-PID and the immune system in this specific population.

The clinical trial involves **healthy volunteers** with circulating neutralizing antibodies (NAbs) against AAV. The study population is composed exclusively of male participants, with an age range categorized as adults. The trial does not include a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their health status, specifically the presence of circulating NAbs against AAV, and no significant lifestyle considerations such as diet or physical activity have been highlighted. The selection criteria do not specify any particular habits or lifestyle factors that would influence participation.

The clinical trial is a **Phase 1** study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers. The trial employs a **randomized**, **double-blind**, and **controlled** design to ensure the reliability and validity of the results. The estimated duration of the trial spans from October 20, 2023, to July 31, 2025, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on specific criteria. This initial visit will involve a thorough evaluation to confirm the presence of circulating **Neutralising antibodies (NAbs) against AAV**. Following successful screening, participants will be randomized into different study groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health status, collect pharmacokinetic and pharmacodynamic data, and assess any adverse events. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the investigational product's effects.

The expected length of participant involvement in the trial is approximately 21 months, contingent upon individual adherence to the study protocol. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to ensure participant safety and the integrity of the collected data, adhering to ethical standards and regulatory requirements.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for any non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of October 20, 2023, and an estimated end date of July 31, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a systematic approach to collect and analyze data, ensuring that the results are scientifically valid and reliable. The study will adhere to rigorous standards to evaluate the potential therapeutic benefits of the investigational product, with a focus on safety and efficacy outcomes. The trial's design and execution will be aligned with regulatory requirements and best practices in clinical research.